Abstract

The design and synthesis of a new class of nonpeptide direct thrombin inhibitors, built on the structure of 1-(pyridin-4-yl)piperidine-4-carboxamide, are described. Starting from a strongly basic 1-amidinopiperidine derivative (6) showing poor thrombin (fIIa) and factor Xa (fXa) inhibition activities, anti-ilia activity and artificial membrane permeability were considerably improved by optimizing the basic PI and the X-substituted phenyl P4 binding moieties. Structure-activity relationship studies, usefully complemented with molecular modeling results, led us to identify compound 13b, which showed excellent fIIa inhibition (K-i = 6 nM), weak anti-Xa activity (K-i = 5.64 mu M), and remarkable selectivity over other serine proteases (e.g., trypsin). Compound 13b showed in vitro anticoagulant activity in the low micromolar range and significant membrane permeability. In mice (ex vivo), 13b demonstrated anticoagulant effects at 2 h after oral dosing (100 mg.kg(-1)), with a significant 43% prolongation of the activated partial thromboplastin time (aPTT), over controls (P < 0.05).

Autore Pugliese

• Caliandro Rocco

Tutti gli autori

• de Candia M.; Fiorella F.; Lopopolo G.; Carotti A.; Romano M.R.; Lograno M.D.; Martel S.; Carrupt P.-A.; Belviso B.D.; Caliandro R.; Altomare C.

Titolo volume/Rivista

Journal of medicinal chemistry

Anno di pubblicazione

2013

ISSN

0022-2623

ISBN

Non Disponibile

Numero di citazioni Wos

Nessuna citazione

Ultimo Aggiornamento Citazioni

Non Disponibile

Numero di citazioni Scopus

Non Disponibile

Ultimo Aggiornamento Citazioni

Non Disponibile

Settori ERC

Non Disponibile

Codici ASJC

Non Disponibile